On Wednesday, CareCloud (NASDAQ:CCLD), a provider of healthcare technology solutions, experienced a change in stock rating by Roth/MKM. The firm downgraded the company's stock from Buy to Neutral and reduced the price target to $3.50 from the previous $5.00. The reassessment follows a detailed analysis of the company's financial outlook and growth potential.
The downgrade comes despite CareCloud's third-quarter revenue of $28.5 million, which met the analyst's expectations. However, the analyst noted that while recent cost-cutting measures have improved CareCloud's cash generation, the growth projections for 2025 do not show significant improvement. Consequently, the analyst has lowered the revenue forecasts for that year.
The company's adjusted EBITDA (AEBITDA) for the third quarter was reported at $6.8 million, an increase from the second quarter's $6.2 million, surpassing the analyst's estimate. This financial performance has positioned CareCloud to consider resuming payment of its preferred dividends in March 2025.
In summary, the revised price target of $3.50 reflects the analyst's new stance on the stock, transitioning from a Buy to a Neutral rating. The decision is based on the lowered revenue forecasts and the expectation that the company's growth will not markedly improve by 2025.
The report emphasizes the financial measures taken by CareCloud, including cost reductions and the potential resumption of preferred dividend payments.
In other recent news, CareCloud, a healthcare technology company, reported a slight dip in its third-quarter earnings with revenue dropping to $28.5 million from $29.3 million the previous year.
However, the company saw a substantial increase in adjusted EBITDA, which rose 111% year-over-year to $6.8 million, and a significant improvement in free cash flow, reaching $10.3 million, a 328% increase from the previous year.
Alongside these financial results, CareCloud announced the full repayment of its credit line and plans to resume dividend payments in March 2025.
The company is also focusing on growth and operational efficiency through its CareCloud CirrusAI platform and an in-house remote patient monitoring (RPM) solution.
Despite a slight revenue decrease, CareCloud reported a positive GAAP net income of $3.1 million, up from a loss of $2.7 million in Q3 2023. The company anticipates annualized net growth by 2025, with a focus on AI and RPM being key to future growth.
While acknowledging some challenges post-acquisition of medSR, the company remains committed to its vision of transforming healthcare technology and delivering value to its shareholders. These are the recent developments in the company's ongoing journey.
InvestingPro Insights
Recent data from InvestingPro adds context to CareCloud's (NASDAQ:CCLD) financial situation and market performance. Despite the downgrade by Roth/MKM, the company's stock has shown remarkable strength, with a 166.39% price return over the past year and a 108.55% return year-to-date. This performance aligns with an InvestingPro Tip indicating a "high return over the last year."
The company's market capitalization stands at $51.4 million, with a price-to-book ratio of 1.19, suggesting the stock may be trading close to its book value. While CareCloud reported a revenue of $111.75 million in the last twelve months, it's important to note that this represents a decline of 11.04% compared to the previous period, which may have contributed to the analyst's decision to lower revenue forecasts.
InvestingPro Tips also highlight that analysts predict CareCloud will be profitable this year, which could be a positive sign for investors despite the current challenges. Additionally, the company's valuation implies a strong free cash flow yield, potentially indicating efficient cash generation—a factor that aligns with the analyst's observation on improved cash generation due to cost-cutting measures.
For readers interested in a more comprehensive analysis, InvestingPro offers 14 additional tips for CareCloud, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.